The government's move to cut GST on medicines and medical devices while exempting lifesaving drugs from the levy is a bold step that will bring direct relief to patients and families while significantly reducing financial strain on them, pharmaceuticals and healthcare industry players said on Thursday.
There is a need to incentivise R&D investments, offer corporate tax concessions and establish an effective intellectual property rights regime in order to push the growth of domestic pharmaceutical industry, as per the industry bodies. Outlining the sector's wish list for the upcoming Union Budget, Organisation of Pharmaceutical Producers of India (OPPI) Director General Anil Matai urged the government to explore methods to incentivise R&D investments, such as deductions on R&D expenses, research-linked incentives for MNCs, and corporate tax concessions.
The government proposes to cut custom duties on Trastuzumab Deruxtecan, Osimertinib and Durvalumab from 10 per cent to nil.
Around 800 people, including children and the elderly, are living in pitiable conditions in relief shelters near Thangjing temple and Moirang Lamkhai which are being run by three organisations.
Three weeks since Principal Mahesh Matai found his 16-year-old son dead outside their Ulhasnagar residence, the Mumbai Police is still clueless about the case.
While it's not difficult to fall prey to card fraud, individuals can protect themselves against losses.
National brands prefer the acquisition route since the southern market is culturally different, reports T E Narasimhan from Chennai.
Sanjay Matai, a financial adviser and author, penned this advice for his son when he got his first job and first paycheque.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances